KemPharm Book Value 2011-2026 | KMPH

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value KemPharm

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
155 M	39.7 M	61.9 M	75.1 M	127 M	-66.4 M	-74.5 M	-66.6 M	-57.5 M	-18.7 M	-10.1 M	-24.3 M	-24.3 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
155 M	-74.5 M	8.93 M

Quarterly Book Value KemPharm

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
133 M	117 M	41 M	39.7 M	69.8 M	-	48.8 M	61.9 M	67.5 M	68.5 M	71.4 M	85.8 M	-	99.2 M	121 M	127 M	132 M	131 M	84.3 M	-66.4 M	-66.4 M	-66.4 M	-66.4 M	-74.5 M	-74.5 M	-74.5 M	-74.5 M	-66.6 M	-66.6 M	-66.6 M	-66.6 M	-57.5 M	-57.5 M	-57.5 M	-57.5 M	-18.7 M	-18.7 M	-18.7 M	-18.7 M	-10.1 M	-10.1 M	-10.1 M	-10.1 M	-24.3 M	-24.3 M	-24.3 M	-24.3 M	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
133 M	-74.5 M	5.04 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	169 M	-	-	$ 28.6 M	USA
AlloVir ALVR	78.8 M	-	4.14 %	$ 49.1 M	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
Midatech Pharma plc MTP	11.4 M	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	-17.1 M	-	-	$ 8.42 M	USA
Aptorum Group Limited APM	13.8 M	$ 0.89	-0.61 %	$ 6.54 M	China
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	733 M	$ 22.57	1.21 %	$ 3.74 B	USA
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Brainstorm Cell Therapeutics BCLI	-9.98 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	188 M	-	-4.8 %	$ 255 M	USA
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Cara Therapeutics CARA	20.9 M	-	-3.03 %	$ 260 M	USA
CASI Pharmaceuticals CASI	108 M	-	-	$ 35.4 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
ChromaDex Corporation CDXC	76.5 M	-	-0.88 %	$ 598 M	USA
Aeterna Zentaris AEZS	3.84 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Aridis Pharmaceuticals ARDS	-24.2 M	-	17.91 %	$ 11.1 M	USA
BioNTech SE BNTX	19.2 B	$ 101.23	-0.82 %	$ 27.2 B	Germany
Checkpoint Therapeutics CKPT	-12.6 M	-	-	$ 169 M	USA
Avenue Therapeutics ATXI	1.83 M	-	-52.27 %	$ 4.45 M	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	-33.7 M	$ 4.09	-0.37 %	$ 437 M	USA
Arcutis Biotherapeutics ARQT	189 M	$ 23.2	-0.96 %	$ 2.95 B	USA
Autolus Therapeutics plc AUTL	178 M	$ 1.48	3.87 %	$ 394 M	Britain
Aptose Biosciences APTO	-27.2 M	-	-45.71 %	$ 1.2 M	Canada
AstraZeneca PLC AZN	48.7 B	-	-	$ 96.9 B	Britain
AVROBIO AVRO	94.7 M	-	1083.1 %	$ 745 M	USA
Can-Fite BioPharma Ltd. CANF	20.3 M	$ 2.9	-0.64 %	$ 4.77 M	Israel
BeiGene, Ltd. BGNE	4.36 B	-	0.49 %	$ 251 B	Cayman-islands
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
bluebird bio BLUE	195 M	-	-	$ 546 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
ContraFect Corporation CFRX	-11.9 M	-	-5.16 %	$ 5.39 M	USA
Cardiff Oncology CRDF	45.4 M	$ 1.71	-0.58 %	$ 114 M	USA
CTI BioPharma Corp. CTIC	-17.6 M	-	-	$ 1.2 B	USA
BioXcel Therapeutics BTAI	-95.5 M	$ 1.07	-1.83 %	$ 13.1 M	USA
Cabaletta Bio CABA	112 M	$ 2.8	-3.95 %	$ 281 M	USA